Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice

被引:25
作者
Brown, MA [1 ]
Nicolai, H
Howe, K
Katagiri, T
Lalani, E
Simpson, KJ
Manning, NW
Deans, A
Chen, P
Khanna, KK
Wati, MR
Griffiths, BL
Xu, CF
Stamp, GWH
Solomon, E
机构
[1] Univ Queensland, Dept Biochem & Mol Biol, St Lucia, Qld 4072, Australia
[2] Univ London Kings Coll, Guys Hosp, Canc Genet Lab, Dept Med & Mol Genet, London SE1 9RT, England
[3] Imperial Canc Res Fund, London WC2A 3PX, England
[4] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia
[5] Imperial Coll Sch Med, Dept Histopathol, London W12 0NN, England
[6] Queensland Inst Med Res, Herston, Qld 4006, Australia
基金
英国医学研究理事会;
关键词
Brca1; dominant-negative; mammary gland; transgenic mice;
D O I
10.1023/A:1020348025139
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To address the hypothesis that certain disease-associated mutants of the breast-ovarian cancer susceptibility gene BRCA1 have biological activity in vivo, we have expressed a truncated Brca1 protein (trBrca1) in cell-lines and in the mammary gland of transgenic mice. Immunofluorescent analysis of transfected cell-lines indicates that trBRCA1 is a stable protein and that it is localized in the cell cytoplasm. Functional analysis of these cell-lines indicates that expression of trBRCA1 confers an increased radiosensitivity phenotype on mammary epithelial cells, consistent with abrogation of the BRCA1 pathway. MMTV-trBrca1 transgenic mice from two independent lines displayed a delay in lactational mammary gland development, as demonstrated by altered histological profiles of lobuloalveolar structures. Cellular and molecular analyses indicate that this phenotype results from a defect in differentiation, rather than altered rates of proliferation or apoptosis. The results presented in this paper are consistent with trBrca1 possessing dominant-negative activity and playing an important role in regulating normal mammary development. They may also have implications for germline carriers of BRCA1 mutations.
引用
收藏
页码:467 / 478
页数:12
相关论文
共 27 条
[1]   Transgenic mouse models of breast cancer [J].
Amundadottir, LT ;
Merlino, G ;
Dickson, RB .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 39 (01) :119-135
[2]   Double indemnity: p53, BRCA and cancer [J].
Brugarolas, J ;
Jacks, T .
NATURE MEDICINE, 1997, 3 (07) :721-722
[3]   Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation [J].
Connor, F ;
Bertwistle, D ;
Mee, PJ ;
Ross, GM ;
Swift, S ;
Grigorieva, E ;
Tybulewicz, VLJ ;
Ashworth, A .
NATURE GENETICS, 1997, 17 (04) :423-430
[4]  
Deng CX, 2000, BIOESSAYS, V22, P728
[5]   Truncated WT1 mutants alter the subnuclear localization of the wild-type protein [J].
Englert, C ;
Vidal, M ;
Maheswaran, S ;
Ge, YM ;
Ezzell, RM ;
Isselbacher, KJ ;
Haber, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (26) :11960-11964
[6]   Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1 [J].
Fan, SJ ;
Yuan, RQ ;
Ma, YX ;
Meng, QH ;
Goldberg, ID ;
Rosen, EM .
ONCOGENE, 2001, 20 (57) :8215-8235
[7]   Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2 [J].
Foray, N ;
Randrianarison, V ;
Marot, D ;
Perricaudet, M ;
Lenoir, G ;
Feunteun, J .
ONCOGENE, 1999, 18 (51) :7334-7342
[8]  
GUDAS JM, 1995, CANCER RES, V55, P4561
[9]  
HABERMANN E, 1992, RECENT ADV TOXINOLOG, V1, P1
[10]   A MUTANT P53 TRANSGENE ACCELERATES TUMOR-DEVELOPMENT IN HETEROZYGOUS BUT NOT NULLIZYGOUS P53 DEFICIENT MICE [J].
HARVEY, M ;
VOGEL, H ;
MORRIS, D ;
BRADLEY, A ;
BERNSTEIN, A ;
DONEHOWER, LA .
NATURE GENETICS, 1995, 9 (03) :305-311